CN101217967B - 镜像异构体的新用途 - Google Patents

镜像异构体的新用途 Download PDF

Info

Publication number
CN101217967B
CN101217967B CN200680024585.4A CN200680024585A CN101217967B CN 101217967 B CN101217967 B CN 101217967B CN 200680024585 A CN200680024585 A CN 200680024585A CN 101217967 B CN101217967 B CN 101217967B
Authority
CN
China
Prior art keywords
nucleic acid
spiegelmer
helix
intracellular
segment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200680024585.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN101217967A (zh
Inventor
F·雅罗施
C·马奇
S·克鲁斯曼
A·沃特
D·尤尔伯格
W·普尔斯克
K·布赫纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TME Pharma AG
Original Assignee
Noxxon Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma AG filed Critical Noxxon Pharma AG
Publication of CN101217967A publication Critical patent/CN101217967A/zh
Application granted granted Critical
Publication of CN101217967B publication Critical patent/CN101217967B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
CN200680024585.4A 2005-05-04 2006-05-04 镜像异构体的新用途 Expired - Fee Related CN101217967B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005020874 2005-05-04
DE102005020874.6 2005-05-04
PCT/EP2006/004180 WO2006117217A2 (de) 2005-05-04 2006-05-04 Neue verwendung von spiegelmeren

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410395203.5A Division CN104293780A (zh) 2005-05-04 2006-05-04 结合hmga的核酸

Publications (2)

Publication Number Publication Date
CN101217967A CN101217967A (zh) 2008-07-09
CN101217967B true CN101217967B (zh) 2014-09-10

Family

ID=36928624

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200680024585.4A Expired - Fee Related CN101217967B (zh) 2005-05-04 2006-05-04 镜像异构体的新用途
CN201410395203.5A Pending CN104293780A (zh) 2005-05-04 2006-05-04 结合hmga的核酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410395203.5A Pending CN104293780A (zh) 2005-05-04 2006-05-04 结合hmga的核酸

Country Status (11)

Country Link
US (2) US8497250B2 (https=)
EP (2) EP1877069A2 (https=)
JP (2) JP2008540363A (https=)
KR (2) KR101418369B1 (https=)
CN (2) CN101217967B (https=)
AU (1) AU2006243334A1 (https=)
BR (1) BRPI0610367A2 (https=)
CA (1) CA2607185A1 (https=)
MX (1) MX2007013760A (https=)
SG (1) SG161311A1 (https=)
WO (1) WO2006117217A2 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
EP2134830A2 (en) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
WO2011098262A2 (en) * 2010-02-09 2011-08-18 Universität Bremen P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth
EP2561079A1 (en) 2010-04-21 2013-02-27 Noxxon Pharma AG Lipid binding nucleic acids
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
CN102375064A (zh) * 2010-08-26 2012-03-14 杭州华得森生物技术有限公司 用酶联免疫法检测人体中hmga2含量的体外诊断试剂盒
DE102010056610A1 (de) * 2010-12-31 2012-07-05 Volker A. Erdmann Pharmazeutische Zusammensetzung enthaltend L-DNA
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
JP2014533098A (ja) * 2011-10-21 2014-12-11 ノクソン・ファルマ・アクチエンゲゼルシャフト グルカゴン結合核酸
BR112014016939A2 (pt) * 2012-01-10 2019-09-24 Noxxon Pharma Ag ácidos nucleicos que se ligam especificamente a cgrp
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
US9233119B2 (en) * 2012-09-27 2016-01-12 Miami University Use of HGMA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells
WO2014193964A2 (en) * 2013-05-28 2014-12-04 Marsha Rosner Prognostic and predictive breast cancer signature
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
DK3092256T3 (da) 2014-01-10 2022-06-20 Birdie Biopharmaceuticals Inc Forbindelser og sammensætninger til immunterapi
CN105233291A (zh) 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN121243402A (zh) 2014-07-09 2026-01-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1组合
KR101755617B1 (ko) 2014-07-23 2017-07-10 한국과학기술연구원 삼차원 자기조립 핵산 나노입자 구조를 갖는 약물전달체
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
JP2017538728A (ja) * 2014-12-19 2017-12-28 ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． イオントフォレシスを用いた生物活性分子の眼内送達
US20180153884A1 (en) 2015-05-31 2018-06-07 Curegenix Corporation Combination compositions for immunotherapy
US10221249B2 (en) 2015-09-10 2019-03-05 Affigen, Llc Method of making patient specific anti-idiotype antibodies
DE17829597T1 (de) * 2016-11-30 2019-12-05 Noxxon Pharma Ag Verfahren zur polyalkoxylierung von nukleinsäuren zur rückgewinnung und wiederverwendung einer überschüssigen polyalkoxylierungsreagenz
WO2020055663A1 (en) * 2018-09-11 2020-03-19 The Texas A&M University System L-oligonucleotide inhibitors of polycomb repressive complex 2 (prc2)
KR20230005908A (ko) * 2020-04-30 2023-01-10 벨라니디 테크놀로지스 엘엘씨 생물학적 또는 화학적 독립체 또는 이벤트를 검출하기 위한 분자 와이어
CN112725438B (zh) * 2021-02-05 2023-08-22 深圳市宝安区妇幼保健院 子宫内膜息肉甲基化标志物组合、检测试剂盒及应用
CN114807183B (zh) * 2021-12-06 2023-06-02 西藏自治区农牧科学院农业研究所 一种青稞矢车菊素氧甲基转移酶基因的新用途
CN118311277B (zh) * 2024-06-11 2024-12-31 北京卫未科学技术有限公司 一种用于癌症早筛和辅助诊断的试剂盒及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051383A2 (de) * 2001-12-19 2003-06-26 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
AU2004203732A1 (en) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Uses of HMGB, HMGN, HMGA proteins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622828A (en) * 1990-06-11 1997-04-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to secretory phospholipase A2 (sPLA2)
JPH09502354A (ja) * 1993-09-08 1997-03-11 ネクスター ファーマスーティカルズ，インコーポレイテッド 核酸リガンドと、同リガンドを製造するための改良された方法
AU728176B2 (en) * 1995-05-04 2001-01-04 Gilead Sciences, Inc. Nucleic acid ligand complexes
US5780611A (en) * 1995-09-15 1998-07-14 Ramareddy Venkata Guntaka Oligomers which inhibit expression of collagen genes
US6171779B1 (en) 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
DE59708838D1 (de) * 1996-08-30 2003-01-09 Jens Peter Fuerste Spiegelselektion und spiegelevolution von nucleinsäuren
DE19726186A1 (de) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
CN1479632A (zh) * 2000-10-09 2004-03-03 用于将核酸导入细胞的复合物
DE10118452A1 (de) * 2001-04-12 2002-10-31 Joern Bullerdiek Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse
ATE469164T1 (de) * 2001-10-26 2010-06-15 Noxxon Pharma Ag Modifizierte l-nukleinsäure
DE10211558A1 (de) * 2002-03-15 2003-10-09 Noxxon Pharma Ag Neue Formen RNAi
WO2003094973A1 (de) * 2002-05-08 2003-11-20 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Mittel und verfahren zum transport von biologisch aktiven molekülen in zellen
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
NZ542687A (en) * 2003-04-13 2010-02-26 Enzon Pharmaceuticals Inc Polymeric oligonucleotide prodrugs
AU2004238076A1 (en) * 2003-05-09 2004-11-25 Novosom Ag Injectable liposomal depots for delivering active ingredients
CA2526853A1 (en) * 2003-05-23 2005-03-03 Board Of Regents - The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
JP2007519724A (ja) * 2004-01-26 2007-07-19 シヴィダ・インコーポレイテッド 核酸を基剤とする治療剤の制御送達および持続的送達
WO2006069782A2 (en) * 2004-12-27 2006-07-06 Silence Therapeutics Ag. Lipid complexes coated with peg and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051383A2 (de) * 2001-12-19 2003-06-26 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
AU2004203732A1 (en) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Uses of HMGB, HMGN, HMGA proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MISHRA, Swaroop等.PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles.《European Journal of Cell Biology》.2004,第83卷(第03期),97-111. *
PATIL, Siddhesh D.等.DNA-based therapeutics and DNA delivery systems: a comprehensive review.《The AAPS Journal》.2005,第7卷(第01期),E61-E77. *
SCALA, Stefania等.Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias.《PNAS》.2000,第97卷(第08期),4256-4261. *
SCHLUETER, Claudia等.HMGA1 proteins in human atherosclerotic plaques.《Pathology - Research and Practice》.2005,第201卷(第2期),101-107.
SCHLUETER, Claudia等.HMGA1 proteins in human atherosclerotic plaques.《Pathology- Research and Practice》.2005,第201卷(第2期),101-107. *

Also Published As

Publication number Publication date
WO2006117217A2 (de) 2006-11-09
CN101217967A (zh) 2008-07-09
JP5766750B2 (ja) 2015-08-19
EP1877069A2 (de) 2008-01-16
MX2007013760A (es) 2008-01-28
AU2006243334A1 (en) 2006-11-09
WO2006117217A3 (de) 2007-08-09
KR101418369B1 (ko) 2014-07-24
KR20080009276A (ko) 2008-01-28
US9074214B2 (en) 2015-07-07
KR20140042941A (ko) 2014-04-07
EP2206501A3 (de) 2010-09-29
JP2013224319A (ja) 2013-10-31
EP2206501A2 (de) 2010-07-14
CA2607185A1 (en) 2006-11-09
SG161311A1 (en) 2010-05-27
US20130337049A1 (en) 2013-12-19
KR101418367B1 (ko) 2014-07-25
CN104293780A (zh) 2015-01-21
US8497250B2 (en) 2013-07-30
JP2008540363A (ja) 2008-11-20
BRPI0610367A2 (pt) 2010-06-15
US20090192100A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
CN101217967B (zh) 镜像异构体的新用途
AU2011267078B2 (en) Cell-penetrating peptides and uses therof
JP4503435B2 (ja) 細胞選択的送達系
CN104293794B (zh) 一种与β‑淀粉样前体蛋白裂解酶1特异性结合的核酸适配子及其应用
JP2006514602A5 (https=)
Haroon et al. A designed recombinant fusion protein for targeted delivery of siRNA to the mouse brain
JP2023512758A (ja) カリクレイン（ｋｌｋｂ１）遺伝子編集のための組成物および方法
Zhang et al. Targeting folded RNA: a branched peptide boronic acid that binds to a large surface area of HIV-1 RRE RNA
KR20140004552A (ko) 페리오스틴에 대한 압타머 및 이를 포함하는 항암제 조성물
JP2017530937A (ja) タンパク質凝集疾患を予防又は治療する方法
CN102459326A (zh) 新的gpcr蛋白及其用途
EP2571989A1 (en) Method for reducing expression of downregulated i renal cell carcinoma i malignant gliomas
HK1119388A (en) Novel use of spiegelmers
EP4413134A1 (en) Adamts14 inhibition
WO2013154128A1 (ja) 新規動脈硬化症治療用医薬組成物及び動脈硬化症治療薬のスクリーニング方法
AU2012241062A1 (en) Novel use of spiegelmers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1119388

Country of ref document: HK

DD01 Delivery of document by public notice

Addressee: Hu Guoqun

Document name: Notice of payment of a single restoration fee

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1119388

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140910

Termination date: 20160504

CF01 Termination of patent right due to non-payment of annual fee